Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
02:00pm, Saturday, 02'nd Dec 2023
After Friday's setback in obesity, Pfizer's shares have now fallen by over 43% year to date. While income investors may have a different take, growth investors may want to use this opportunity to lowe
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
08:00am, Saturday, 02'nd Dec 2023
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades.
5 Top Stocks to Buy Before 2024
05:00am, Saturday, 02'nd Dec 2023
Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar
Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setback
06:28pm, Friday, 01'st Dec 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk Pfizer's weight-loss pill setback.
Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side Effects
12:30pm, Friday, 01'st Dec 2023
Pfizer (PFE) was the worst-performing stock in the S&P 500 Friday as shares dropped over 4% in early trading after the drug maker announced it was ending development of a twice-a-day weight-loss pill
Why Pfizer Stock Is Sinking Today
11:51am, Friday, 01'st Dec 2023
Pfizer announced that it won't advance a twice-daily version of weight-loss pill danuglipron into phase 3 testing. The decision was made due to high rates of side effects and discontinuations in a pha
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
11:22am, Friday, 01'st Dec 2023
Pfizer (NYSE: PFE ) layoffs are on the way for employees at its Groton, Conn. location as part of a wider cost-cutting effort at the pharmaceutical company.
Pfizer Scraps Obesity Pill Study, Stock Hits 3-Year Lows
10:55am, Friday, 01'st Dec 2023
Pfizer Inc (NYSE:PFE) has been trying to nudge its way into the weight-loss drug buzz with its own twice-daily version called danuglipron.
Pfizer shares knocked by fat drug trial setback
10:41am, Friday, 01'st Dec 2023
Shares in Pfizer Inc (NYSE:PFE) dropped 6% after its highly touted weight loss pill danuglipron showed significant side effects, stopping people from using it. Pfizer will now focus on a once-dail
Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low
09:43am, Friday, 01'st Dec 2023
Investors' have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight loss drug makers Eli Lilly (shares up 60%) and Novo Nordisk (shares up
Pfizer Stops Developing Weight-Loss Pill
07:40am, Friday, 01'st Dec 2023
Pfizer stops developing its experimental weight-loss pill. More than half of patients in the study had to stop taking danuglipron due to nausea and vomiting, according to a statement Friday.
Pfizer's Weight Loss Drug Won't Enter a Phase 3 Trial. The Stock Drops.
07:34am, Friday, 01'st Dec 2023
'We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm,' Pfizer said.
Pfizer's stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation
06:58am, Friday, 01'st Dec 2023
Pfizer Inc.'s stock PFE, +1.30% fell 4% premarket Friday, after the company said it's not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adults w
Pfizer drops plan to study twice-daily obesity pill in late-stage studies
06:49am, Friday, 01'st Dec 2023
Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates of si
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
06:45am, Friday, 01'st Dec 2023
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
